Nanobiotix Q3 Update Highlights Strategic Moves: Phase 3 Head And Neck Cancer Trial Transferred To Janssen, Curadigm Platform Expansion; €53.2M Cash Reserves
Nanobiotix Q3 Update Highlights Strategic Moves: Phase 3 Head And Neck Cancer Trial Transferred To Janssen, Curadigm Platform Expansion; €53.2M Cash Reserves
Nanobiotix第三季度更新重点：头颈部癌症第三阶段试验转移至Janssen，Curadigm平台扩张；现金储备5320万欧元
- Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submission
- Added expert industry leaders to Supervisory Board, further strengthening support for the Company's long-term growth strategy
- NBTXR3 program update from pancreatic cancer study and lung cancer study with MD Anderson expected 4Q 2024 and 1H 2025, respectively
- Update on expansion of product portfolio to include disruptive nanotherapeutic platform Curadigm expected 4Q 2024
- €53.2 million in cash and cash equivalents as of September 30, 2024 with cash runway into 4Q 2025
- 将NANORAY-312头颈癌全球三期研究的美国赞助转移，这是为潜在NBTXR3监管提交做准备的关键一步
- 向监事会增加专业行业领袖，进一步加强对公司长期增长策略的支持
- 预计NBTXR3项目更新包括胰腺癌研究和肺癌研究，预计分别在2024年第4季度和2025年上半年由MD Anderson进行
- 预计产品组合扩展包括颠覆性纳米治疗平台Curadigm，预计在2024年第4季度推出
- 截至2024年9月30日，现金及现金等价物为€5320万，现金储备可支持至2025年第4季度
资讯热榜
更新时间